Myotonic dystrophy type 1 (DM1) is caused by toxicity of an expanded, noncoding (CUG)n tract in DM protein kinase (DMPK) transcripts. According to current evidence the long (CUG)n segment is involved in entrapment of muscleblind (Mbnl) proteins in ribonuclear aggregates and stabilized expression of CUG binding protein 1 (CUGBP1), causing aberrant premRNA splicing and associated pathogenesis in DM1 patients. Here, we report on the use of antisense oligonucleotides (AONs) in a therapeutic strategy for reversal of RNA-gain-of-function toxicity. Using a previously undescribed mouse DM1 myoblast؊myotube cell model and DM1 patient cells as screening tools, we have identified a fully 2-O-methyl-phosphorothioatemodified (CAG)7 AON that silences mutant DMPK RNA expression and reduces the number of ribonuclear aggregates in a selective and (CUG)n-length-dependent manner. Direct administration of this AON in muscle of DM1 mouse models in vivo caused a significant reduction in the level of toxic (CUG)n RNA and a normalizing effect on aberrant premRNA splicing. Our data demonstrate proof of principle for therapeutic use of simple sequence AONs in DM1 and potentially other unstable microsatellite diseases.
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antisense oligonucleotide ͉ microsatellite ͉ muscle ͉ pathogenesis ͉ RNA silencing M yotonic dystrophy type 1 (DM1) is the most common neuromuscular dystrophy in adults and the first triplet-repeat RNA-mediated disorder described (1, 2) . Its complex, multisystemic pathology involves the production of toxic (CUG)n transcripts after expansion of a mutant (CTG)n tract in the DMPK gene. In DM1 patients with expansions ranging from 50 to Ͼ2,000 triplets in their blood DNA severity of disease correlates to (CTG)n tract length.
Currently, the weight of evidence argues in favor of a model in which the harmful effect of a mutation in the DMPK gene occurs at the gene product level and involves protein binding to the long (CUG)n segment. Other cell stress effects of expression of the mutant DMPK gene cannot be excluded, however (1, 2) . Members of the Mbnl and CELF families of RNA-binding proteins are most likely implicated in DM1 pathogenesis (3, 4) . Mbnl1 is sequestered together with expanded (CUG)n transcripts in ribonucleoprotein (RNP) aggregates, resulting in reduced free Mbnl1 levels in the cell. Conversely, steady-state levels of CUGBP1 are increased in cells or tissues with a high (CUG)n dose. The ensuing imbalance in splicing factors causes missplicing of several transcripts, usually resulting in expression of fetal proteins inappropriate for adult tissue (2) .
Use of DM1 mouse models has pointed out that harmful effects of toxic (CUG)n RNA are largely reversible. For the HSA LR model (5) , characterized by high expression of skeletal ␣-actin transcripts bearing a (CUG)250 tract, it was demonstrated that viral overexpression of Mbnl1 reverses splicing defects and alleviates myotonia (6) . In 5-313 mice, which inducibly overexpress the human DMPK (hDMPK) 3Ј-UTR including a (CUG)5 repeat tract as part of a GFP transcript, typical DM1 myotonia and cardiac defects disappeared when the transgene was silenced (7) . These observations underscore the idea that reducing (CUG)n RNA dosage is beneficial to patients and forms an attractive therapeutic goal for improvement of DM1 features.
Here, we investigated the feasibility of antisense oligonucleotide (AON) technology, which has shown a range of promising applications (8) (9) (10) (11) . Among a series of chemically modified AONs designed to induce posttranscriptional gene silencing of mutant hDMPK transcripts a (CAG)7 AON was identified that causes specific reduction of expanded (CUG)n transcripts and reverses DM1 features in cell and mouse models. We demonstrate that an effective, therapeutic strategy based on an AON consisting of simple repeats may become feasible, which may also have bearing for other microsatellite disorders.
Results

A Novel Myogenic Cell Model for DM1.
As a model for testing DM1-specific AONs in vitro, we derived conditionally immortalized myoblast-myotubes from skeletal muscle of the DM300 lineage ( Fig. 1A) (12) . DM300 mice were originally generated as carriers of a hDMPK (CTG)300 transgene, but ongoing expansion was observed in this lineage. The DM1 repeat locus in our cell model at the time of derivation comprised around 500 triplets. Hence, we will refer to these cells as DM500 myoblasts/myotubes. DM500 myoblasts expressed hDMPK (CUG)500 mRNA at levels comparable to those of endogenous mouse DMPK (mDMPK) mRNA (Fig. 1B) . Ribonuclear foci, a hallmark of DM1 pathogenesis (13) , were observed in proliferating myoblasts and in differentiated myotubes (Fig. 1C) . FISH using a (CAG)7 probe confirmed the presence of 5 to 10 foci per nucleus, not seen with a (CUG)7 control. Altogether, our DM500 cells displayed molecular characteristics of DM1, which makes them a useful test system for AON effects on cell stress caused by mutant hDMPK transcripts. suppress hDMPK (CUG)500 RNA expression in DM500 myotubes. Northern blotting revealed that silencing capacity varied between AONs (Fig. 2B ). PS58, a 2Ј-O-methyl (2Ј-OMe) phosphorothioate (PT) modified (CAG)7 oligo designed to target the (CUG)n segment was most effective, causing a Ϸ90% reduction in hDMPK (CUG)500 mRNA (Fig. 2C ). Not surprisingly, endogenous mDMPK mRNA bearing a (CUG)2(CAG)2(CUG) sequence instead of an uninterrupted (CUG)n segment was left intact. To ensure that our appraisal of PS58's silencing capacity was correct and that the disappearance of hDMPK (CUG)500 mRNA signal was not the result of events that occurred during the RNA isolation procedure, we tested various methods (Fig. S1 ) and also carried out RT-PCR analysis across the hDMPK transcript (Fig. 2D) . Data obtained are consistent with a breakdown of hDMPK (CUG)500 transcripts by PS58. For reasons unknown, the 5Ј region (exons 1-7) of the mRNA appeared relatively resistant to degradation compared to 3Ј regions (Fig. 2D) . In this respect, it is important to note that no short DMPK mRNA products of discrete size were detected on Northern blot or by RT-PCR.
Examination of time and concentration effects revealed that maximal efficacy of PS58 in our DM500 cell model was already reached within 2 hours after transfection (Fig. 3A) . hDMPK Northern blot analysis to detect ability of AONs to silence hDMPK mRNA in DM500 myotubes. Gapdh was used as loading control. Oligos were tested at least twice; a representative blot is shown. (C) PS58, directed at the (CUG)n segment, was the most successful AON (P Ͻ 0.001, n ϭ 19). (D) PS58 activity was corroborated by semiquantitative RT-PCR analysis of individual segments of the hDMPK transcript (primers indicated with black arrows). Numerals in lanes indicate relative abundance to mock samples (set at 100), using ␤-actin for normalization. A representative result from 2 experiments is shown. (E) A reduction in the number of nuclei containing (CUG)n foci was observed after PS58 treatment of DM500 myoblasts (P Ͻ 0.001, n ϭ 4).
(CUG)500 mRNA levels remained virtually undetectable for up to 10 days after a single oligo dose ( Fig. 3 B and C) . From concentration response analyses, we deduced an IC50 of 0.40 Ϯ 0.15 nM (Fig. 3D) . Combined, our studies demonstrated that PS58 silenced expanded hDMPK transcripts quickly and with high affinity. Because PS58 is a (CAG)7 triplet repeat oligonucleotide, (CUG)n-bearing transcripts other than DMPK could potentially serve as targets too. We searched databases for (CUG)n tracts in the mouse transcriptome and identified 9 candidate transcripts that contain at least 6 CUG triplets (Table S2) . RT-PCR-mediated quantification of 4 candidates revealed that PS58 treatment only marginally affected expression; for Mapkap1 (CUG)26 transcripts, a more pronounced effect was noted at high PS58 concentration (Fig. S2) .
In Human Cells, PS58 Preferentially Silences DMPK Transcripts with an
Expanded (CUG)n Repeat. Symptoms in DM1 strongly correlate with the length of the (CTG)n segment in the mutated DMPK allele (1).
To be functional in patients, PS58 should ideally silence transcripts from the expanded allele and not be active toward transcripts from the normal-sized allele, which may carry up to 37 triplets (14) . To test this requirement, we analyzed PS58 efficacy in 4 patient myoblast cultures (15) . These myoblasts expressed transcripts from expanded alleles that contained 200, 800, 1,400, or 2,000 CTG triplets, representing different severities of disease, and normalsized alleles bearing 5, 13, or 21 triplets. Northern blot analysis demonstrated that PS58 silenced expanded DMPK transcripts in these human cells to the same degree as in DM500 mouse myotubes (Fig. 4 A and B) . PS58 efficacy clearly correlated with the number of CUG triplets in the hDMPK transcript since normal-sized transcripts were only mildly reduced (Fig. 4 A-C) . Effects on nonmutant transcripts appeared variable, as (CUG)13 transcripts were reduced in 13/800 cells, but unchanged in 13/2,000 cells. Western blot analysis confirmed that undesired silencing of normalsized transcripts did not result in great loss of DMPK protein, as 71% of control level was still present at 72 h after PS58 treatment in 21/200 myoblasts (Fig. 4 D and E) . Secondary Effects of PS58 Activity in DM500 Cells. Next, we used our DM500 cell model to examine whether PS58 treatment had beneficial effects on the DM1-typical formation of nuclear RNA foci or occurrence of embryonic modes of premRNA splicing. Muscleblind proteins and CUGBP1 are prominently involved in these events (2) . FISH analysis demonstrated that PS58 treatment caused a 4-fold reduction in the percentage of cells that contained ribonuclear foci (Fig. 2E) . The presence of PS58 had no effect on CUGBP1 level, but it should be noted that the CUGBP1 level in DM500 myotubes was not increased compared to controls (similar to DM500 mice). Also the pattern of alternative splicing of a representative subset of DM1-specific transcripts was not altered in the presence of PS58 in DM500 myotubes or WT myotubes (Fig.  S3 ). This excludes anomalous effects of PS58 on RNA processing. Effects of PS58 activity on splicing required study in vivo, as the terminal end stage of myogenic differentiation and adult programming of RNA processing cannot be achieved in cells in culture (Fig. S3 ).
PS58 Is Active in DM1 Mouse Models in Vivo. As a prelude to in vivo experiments, we investigated the distribution of fluorescently labeled PS58 after injection into the GPS (gastrocnemius-plantarissoleus) complex of DM500 mice. A nonhomogeneous staining was observed throughout the tissue (Fig. S4A ). Virtually no signal was found in the tibialis anterior (TA) demonstrating that intertissue spreading was minimal. Analysis of muscle sections showed that PS58 molecules concentrated in cell nuclei (Fig. S4B) .
Next, we assessed efficacy of PS58 in 2 different mouse models. In DM500 mice, injection in the GPS complex followed by RT-PCR analysis of RNA content confirmed silencing of hDMPK (CUG)500 mRNA in the gastrocnemius and plantaris, but not the TA control (Fig. 5A) . Again, the 5Ј end of the hDMPK transcript appeared relatively resistant to degradation (Fig. S5) . PS58 injection in the GPS complex of HSA LR mice (5) resulted in significant silencing of toxic (CUG)250 transcripts, predominantly in soleus and to a lesser extent in gastrocnemius (Fig. 5B) .
The very high expression of transgenic transcripts in the HSA LR mouse culminates in formation of large RNP foci in every cell nucleus in skeletal muscle, which makes it a particular attractive model for examining effects of PS58 treatment on this feature. We categorized appearance of RNP foci according to FISH signal intensity and pattern after PS58 treatment and observed a significant shift from nuclei packed with foci toward nuclei containing smaller, discrete foci (Fig. 5C ). No nuclei void of foci were detected. Simultaneous study of nuclear aggregation behavior of Mbnl1 in this model revealed a substantially more diffuse distribution of Mbnl1 ( Fig. S6) (6) .
Many embryonic splice modes in skeletal muscle observed in DM1 patients are replicated in HSA LR mice (16)-in contrast to DM500 mice, which display hardly any DM1-typical splice modes in skeletal muscle and also RNP foci much less overtly (21) . We measured splice modes of 5 different transcripts-Serca1, Mbnl1, Ttn, Clcn1, and Tnnt3-upon PS58 treatment in TA and GPS muscles. In electroporated TA muscle, a reduction of Ϸ50% of HSA LR mRNA was achieved after 7 days, which was paralleled by a significant shift in splicing pattern from an embryonic-like (E) to normal-adult (A) mode for 4 out of 5 transcripts tested ( Fig. 5D and Fig. S7 ).
Finally, we combined all data obtained with HSA LR mice, irrespective of the mode of PS58 administration, muscle type, or timing of muscle isolation. Collective evaluation of the results revealed a clear correlation between PS58-induced reduction of HSA LR (CUG)250 mRNA levels and the accompanying effects on splicing (i.e., splice-ratio correction, defined as the mock-treated embryonic:adult splice ratio divided by the PS58-treated embryonic:adult splice ratio; Fig. 5E ). This demonstrated that PS58-induced suppression of abnormally expanded (CUG)n RNA mitigates toxicity effects in vivo.
Discussion
DM1 was the first RNA toxic-gain-of-function disorder described (2). Here, we explored a therapeutic approach that directly deals with its root cause, i.e., expression of expanded (CUG)n RNA. Only few experimental studies were dedicated in the past to the breakdown of normal or mutant hDMPK RNA, all restricted to use of cell models and mostly viral-based vectors for the delivery of the active component (17) (18) (19) (20) . To circumvent problems associated with viral-based therapy in humans, we chose AONs to degrade toxic (CUG)n RNA. The (CAG)7 AON PS58 identified in this paper was successfully delivered into cells with the help of transfection reagents or locally via injectionelectroporation protocols in mouse muscle, to demonstrate proof of principle. The chemical nature of PS58 precludes efficient uptake in tissues. We will therefore need to concentrate on the design of more sophisticated delivery techniques to promote uptake in vivo, before we can proceed with a study of systemic treatment of DM1 animal models or patients. Clearly, this remains a challenge for future efforts.
PS58 silencing capacity for expanded (CUG)n RNA ranged from up to 90% in cells to between 30 and 80% in vivo, with differences between muscle types (soleus Ͼ gastrocnemius ϳ tibialis anterior Ͼ plantaris). The HSA LR and DM500 models clearly differ in the degree of muscle pathology, presumably because the level of expanded (CUG)n transcripts in muscle from the HSA LR model is much higher than in DM500 muscle. Still, a similar range of silencing was observed for muscles of both models. On the basis of these observations, we think that membrane integrity or physiological state of individual muscle types, rather than the initial cellular concentration of target RNA forms the most important parameter for AON uptake and breakdown capacity. Also size of the (CUG)n segment or differences in sequence context or subcellular localization of target RNAs are considered parameters of lesser importance.
Studies of Mbnl1 protein overexpression in HSA LR mice (6), expression inhibition of a (CUG)5 RNA-encoding transgene in an inducible mouse model (7) or correction of Clcn1 splicing (11) have illustrated that particular DM1 features are reversible. Our findings demonstrate that also nongenetic modalities, e.g., treatment with a simple repeat AON, can reverse DM1 pathogenesis in vivo. Our findings on the PS58-induced reduction of nuclear RNP foci are in line with the notion that foci containing (CUG)n RNA, Mbnl1 protein, and potentially other unknown factors are dynamic structures (2) . We therefore may assume that upon degradation of the (CUG)n RNA component, less Mbnl1 will be captured in the aggregated state and more Mbnl1 will be available for regulation of splicing. Our findings in the HSA LR model confirm this idea. PS58 treatment significantly improved splicing of 5 different transcripts, in a manner clearly correlating to the degree of (CUG)n RNA reduction in this model.
Whether the (CUG)n repeat dose, splice abnormalities, and phenotypic features in HSA LR mice accurately reflect the situation in patients is a hotly debated question in the DM field. The disbalance introduced by transgene expression in the currently available models may be considered either too extreme (e.g., the HSA LR model) or too mild (e.g., DM500 model). Further progress in knowledge on this topic is needed before we can productively proceed with studies toward the development of PS58-based therapy. Analysis on the reversal of phenotype in DM1 mouse models and its value for prediction of possible effectiveness in clinical trials in DM1 patients therefore needs further work.
Our AONs were originally designed to bind and degrade expanded (CUG)n RNA or induce exon skipping (compare ref. 22) or abortive splicing (23) . The unique effectiveness of PS58 can best be explained by induction of selective breakdown, presumably starting at the 3Ј target segment with the (CUG)n tract, as we noticed relatively stable behavior of the 5Ј part of the hDMPK transcripts. Currently, we do not know much about the molecular mechanism involved in this breakdown, but do not expect that PS58, being an AON with a 2Ј O-methyl-based backbone, will work via recruitment of RNase H. Selective effects of PS58 on premRNA processing events, like the use of premature polyadenylation sites or complete skipping of exon 15 or segments thereof, can also not be involved as no smaller DMPK mRNA products of discrete size were identified using RT-PCR or Northern blot analyses. PS58-induced breakdown of repeat expanded transcripts in DM500 myotubes was fast and went nearly to completion. So we assume that both the cytoplasmic mature mRNA pool (constituting probably only a minor fraction) and the nuclear pool of primary and mature expanded (CUG)n transcripts served as targets. Moreover, in patient cells we observed effects on nonmutant DMPK transcripts residing in the cytoplasm. Thus, an exclusive effect of PS58 in the nucleus seems unlikely.
It is known that 2Ј-OMe PT modifications, as in PS58, protect against enzymatic breakdown in the cell, resulting in higher AON efficacy (9) . The PT moiety is probably also responsible for the dominant nuclear localization that we observed for PS58 (24) . A fully modified 2Ј-OMe PT AON has to our knowledge not been used successfully before in antisense silencing strategies (9, 25, 26) . Our data suggest that the structural composition of PS58 determines entry in novel RNA degradation mechanisms, but this will require further testing.
Regardless of the mechanism operating, we have observed that PS58 provides selectivity between expanded and normal-sized hDMPK transcripts. Patients carrying a normal-sized allele in the (CTG)18-37 range are only present in Ϸ10% of the DM1 population (14) and also other transcripts with a (CUG)n Ն 10 segment are scarce in the human transcriptome (Table S3) . From a kinetic point of view, it is important to note that PS58 has multiple binding sites on a long (CUG)n segment but only 1 or a few on a normal (CUG)n segment. Assuming that binding of 1 oligo to a (CUG)n transcript is sufficient for degradation, a lower dose may thus increase selectivity and reduce the chance of undesired side effects. Changing the number of CAG triplets in the AON could also positively influence selectivity. Although at this point, unfamiliar with the working mechanism of PS58, it is impossible to predict whether a shorter or longer (CAG)n AON will be equally effective. Experiments with (CAG)n AONs of different lengths in cells expressing DMPK transcripts with diverse (CUG)n segments should provide answers.
Successful development of RNA-directed therapy for DM1 will also create new opportunities for treatment of other microsatellite diseases caused by RNA toxicity, like DM2, SCA8, SCA10, FRAXA, and HDL2, but maybe also disorders like Huntington's or oculopharyngeal muscular dystrophy. Each of these diseases progressively affects muscle, heart, and brain and functioning of various body systems. For none of these disorders is a cure or therapy available.
Materials and Methods
For details see SI Materials and Methods.
Animals. DM500 mice, derived from the DM300 -328 line (12) , and HSA LR 20b mice have been described (5) . All animal experiments were approved by the Institutional Animal Care and Use Committees of the Radboud University Nijmegen and the University of Rochester Medical Center.
Cell Culture. An immortal mouse myoblast cell culture expressing hDMPK (CUG)500 transcripts was derived from GPS tissue isolated from DM500 mice additionally expressing 1 copy of the H-2K b -tsA58 allele. The generation of human DM1 myoblast lines has been described (15).
Oligos. All AONs used in this study are listed in Fig. 2A and Table S1 . PS58 is a synthetic RNA oligonucleotide with sequence 5Ј-CAGCAGCAGCAGCAGCAG-CAG-3Ј, which carries full-length 2Ј-OMe-substituted ribose molecules and PT internucleotide linkages.
Oligo Transfection. Cells were transfected with AONs complexed with polyethyleneimine (PEI; ExGen500, Fermentas) according to the manufacturer's instructions.
RNA Isolation. RNA from cultured cells was isolated using the Aurum Total RNA mini kit (Bio-Rad) according to the manufacturer's protocol. RNA from muscle tissue was isolated using TRIzol reagent (Invitrogen). Alternative methods are described in SI Materials and Methods.
Northern Blotting and RT-PCR. Northern blotting and semiquantitative RT-PCR analysis were done following standard procedures. For analysis of alternative splicing, embryonic (E):adult (A) splice ratio was defined as embryonic form signal divided by adult form signal in each sample. Splice ratio correction illustrates the effect of PS58 treatment on alternative splicing. Splice ratio correction is defined as the mock-treated embryonic:adult splice ratio divided by the PS58-treated In Vivo Treatment. The GPS complex of DM500 mice was pretreated with PEI-5% glucose injections on days 1 and 2. This pretreatment was followed by 2 injections with 2 nmoles of PS58 in a PEI-5% glucose solution on days 3 and 4. Mock-treated mice received the same treatment except that oligo PS58 was left out. Mice were killed and muscles were isolated on day 15 .
Diverse treatment protocols were tested in HSA LR mice. In each case, 1 leg of a HSA LR mouse was treated with 1 or 2 nmoles PS58, while the contralateral leg served as mock control. (i) HSA LR mice were injected twice in the GPS complex as described above, without PEI pretreatment. Injections took place at days 1 and 8, and tissues were isolated on day 22. Noninjected TA muscle served as negative control. (ii) TA muscle was injected once as described above, without PEI pretreatment, and muscle tissue was isolated 7 days later. (iii) TA muscle was injected with or without PEI, followed by electroporation (11) and analyzed on day 8 or 15.
Immunofluorescence and FISH.
Immunofluorescence and FISH were performed by standard methods. Images were collected on a Zeiss Axioplan fluorescence microscope (Carl Zeiss). Pictures were captured by a Zeiss AxioCam MR camera with Axiovision 3.1 software.
Intratissue Imaging. The distribution of FAM-labeled PS58 was imaged in the GPS complex of DM500 mice with the Olympus OV110 whole mouse imaging system (Olympus).
Statistical Analysis. See details in SI Materials and Methods.
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SI Materials and Methods
Animals. Hemizygous DM500 mice, derived from the DM300-328 line (1), express a transgenic human DM1 locus, which bears a repeat segment that has expanded to Ϸ500 CTG triplets, because of intergenerational triplet-repeat instability. For the isolation of immortal DM500 myoblasts, DM500 mice were crossed with H-2K b -tsA58 transgenic mice (2) . Homozygous HSA LR 20b mice express a (CUG)250 segment in the context of a human skeletal actin transcript (3). All animal experiments were approved by the Institutional Animal Care and Use Committees of the Radboud University Nijmegen and the University of Rochester Medical Center.
Cell Culture. An immortal mouse myoblast cell culture expressing hDMPK (CUG)500 transcripts was derived from GPS tissue isolated from DM500 mice additionally expressing 1 copy of the H-2K b -tsA58 allele (4). Independent myoblast lines were obtained by ring cloning. The DM500 myoblast culture used in this study consisted of an equal mixture of 6 independent clones. Likewise, a wild-type myoblast culture was derived from wildtype littermates from the DM500 mouse line and expressed only the H-2K b -tsA58 allele. Conditionally immortalized myoblasts were grown on gelatincoated dishes in DMEM (Gibco) supplemented with 20% (vol/vol) FCS, 50 g/mL gentamycin, 20 units ␥-IFN/mL (BD Biosciences) and 2% (vol/vol) chicken embryo extract (Sera Laboratories International) at 5% CO 2 and 33°C. Differentiation to myotubes was induced by placing DM500 myoblasts, grown to confluency on Matrigel (BD Biosciences), in DMEM supplemented with 5% (vol/vol) horse serum (HS) and 50 g/mL gentamycin at 37°C. These low serum conditions were continued for a maximum of 10 days. Spontaneous contractions appeared around 5 days of differentiation.
For the generation of human DM1 myoblast lines biopsies from quadriceps muscles were obtained during autopsies, in accordance with French legislation on ethical rules. Satellite cells were isolated from DM1 fetal muscle as described (5) . Myoblasts were maintained in Ham's F-10 medium supplemented with 20% FCS and 25 g/mL gentamycin, at 5% CO 2 and 37°C.
Analysis of (CTG)n Repeat Lengths. Sizes of the expanded (CTG)n segments in the human cell lines were estimated via Southern blotting of genomic DNA (5). The number of CTG triplets in the normal-sized alleles was determined by PCR and DNA sequencing.
AONs. The design of AONs was primarily based on open secondary structures in hDMPK mRNA as predicted by Mfold software (6) . PS58 is a synthetic, modified RNA molecule with sequence 5Ј-CAGCAGCAGCAGCAGCAGCAG-3Ј, which carries full-length 2Ј-OMe-substituted ribose molecules and PT internucleotide linkages. All AONs used in this study, their chemistry, sequence, and position along the hDMPK transcript are listed ( Fig. 2A, and Table S1 ). All AONs were provided by Prosensa B.V. Oligo Transfection. Unless specified otherwise, cells were transfected with AONs complexed with polyethyleneimine (PEI; ExGen500, Fermentas), according to the manufacturer's instructions. Typically, 5 L of PEI per g of AON was added in differentiation medium to myotubes on day 5 of myogenesis or in Opti-MEM (Invitrogen) to myoblasts, in both cases at a final oligo concentration of 200 nM. Fresh medium was supplemented after 4 hours. After 24 h, medium was changed. RNA was isolated 48 h after transfection.
RNA Isolation. Typically, RNA from cultured cells was isolated using the Aurum Total RNA mini kit (guanidine-HCl/ mercaptoethanol-based lysis, silica membrane binding; BioRad), according to the manufacturer's protocol. RNA from muscle tissue was isolated using TRIzol reagent (Invitrogen). Alternative methods to isolate RNA from cultured cells involved: (i) use of the TRIzol reagent, according to the manufacturer's protocol; (ii) an oligo(dT) affinity column (NucleoTrap mRNA mini kit; Macherey-Nagel) for the isolation of poly(A) RNA; or (iii) a TRIzol procedure preceded by a proteinase K digestion of the whole cell lysate (7): in short, cells were lysed in 500 mM NaCl, 10 mM Tris-HCl, pH 7.2, 1.5 mM MgCl 2 , 10 mM EDTA, 2% SDS, and 0.5 mg/mL proteinase K for 45 min at 45°C. Nucleic acids were precipitated with 2.5 volumes ethanol and collected by centrifugation. Precipitates were then processed following the standard TRIzol procedure.
Northern Blotting. RNA was electrophoresed in a 1.2% agaroseformaldehyde denaturing gel. Depending on the source and the isolation procedure, 1 to 15 g RNA per lane was loaded. RNA was transferred to Hybond-XL nylon membrane (Amersham Pharmacia Biotech) and hybridized with random-primed 32 Plabeled probes (2.6 kb hDMPK cDNA (covering the entire ORF and 3Ј-UTR; i.e., the 3Ј part of exon 1 and all exons 2-15), 1.1 kb rat Gapdh cDNA or 1.1 kb mouse Mapkap1 cDNA) or 32 P-end-labeled (CAG)9 or mouse skeletal actin-specific (MSA) oligos (3). Blots were exposed to X-ray film (X-Omat AR, Kodak). Quantification of signals was done by phospho-imager analysis (GS-505 or Molecular Imager FX, Bio-Rad) and analyzed with Quantity One (Bio-Rad) or ImageJ software. Gapdh/ GAPDH or MSA levels were used for normalization. RNA levels for control samples were set at 100.
Semiquantitative RT-PCR Analysis. Approximately 0.5 g RNA was subjected to cDNA synthesis with random hexamers using the SuperScript first-strand synthesis system (Invitrogen) in a total volume of 20 L. One L of cDNA preparation was subsequently used in a semiquantitative PCR analysis according to standard procedures. In RT Ϫ control experiments, reverse transcriptase was omitted. A repeat-primed RT-PCR assay was developed for the hDMPK (CUG)n segment as described (8, 9) . PCR primers were designed on the basis of NCBI database sequence information (see list of primers below). Product identity was confirmed by DNA sequencing. The signal for ␤-actin was used for normalization. Cycle number was 18 for ␤-actin and 23-31 for other primer sets. The repeat-primed RT-PCR in exon 15 was analyzed after 36 cycles. PCR products were analyzed on 1.5-2.5% agarose gels, stained by ethidium bromide. Quantification of signals was done using the Labworks 4.0 software (UVP BioImaging Systems). Values for control samples were set at 100. Human DMPK mRNA levels in DM500 cells and mice were quantified with 5 independent primer sets covering almost the entire transcript.
For analysis of alternative splicing, embryonic (E):adult (A) splice ratio was defined as embryonic form signal divided by adult form signal in each sample. Splice ratio correction illustrates the effect of PS58 treatment on alternative splicing. Splice ratio correction is defined as the mock-treated embryonic:adult splice ratio divided by the PS58-treated embryonic:adult splice ratio for a given transcript per mock/PS58-treated muscle pair (i.e., per mouse). Hence, a splice ratio correction of 1.0 means no change in alternative splicing, while a correction Ͼ1.0 implies an increase in adult splice forms. In the analysis of HSA LR mRNA levels versus splicing correction, splice ratio corrections of 5 transcripts (i.e., Serca1, Mbnl1, Ttn, Clcn1, and Tnnt3) were averaged per muscle pair. A total of 27 different muscle samples, originating from 20 mice, were included.
The following primers were used: hDMPK exon 15-F; 5Ј-GGGGGATCACAGACCATT-3Ј; hDMPK exon 15-R; 5Ј-TCAATGCATCCAAAACGTGGA-3Ј; hDMPK exon 12-exon 15-F; 5Ј-AAAGAATTCGGGAC-CTAGAGGCACACGT-3Ј; hDMPK exon 12-exon 15-R; 5Ј-AAACTCGAGCGAA-CAGGAGCAGGGAAA-3Ј; hDMPK exon 7-exon 9-F; 5Ј-ACGGCGGAGACCTATG-GCAA-3Ј; hDMPK exon 7-exon 9-R; 5Ј-TCCCGAATGTCCGA-CAGTGT-3Ј; hDMPK exon 1-exon 7-F; 5Ј-CGAACTGGCCCAGGA-CAAGTA-3Ј; hDMPK exon 1-exon 7-R; 5Ј-TACACCCAGCGCCCAC-CAGT-3Ј; hDMPK exon 15 repeat-F; 5Ј-GGTCCTTGTAGCCGG-GAAT-3Ј; hDMPK exon 15 repeat-R; 5Ј-GCGTCATGCACA A-GAAAGCTTT-3Ј; hDMPK exon 15 repeat-anchored; 5Ј-GGTCCTTGTAGC-CGGGAATGCTGCTGCTGCTGCTGCT-3Ј;
␤-actin-F; 5Ј-GCTAYGAGCTGCCTGACGG-3Ј; ␤-actin-R; 5Ј-GAGGCCAGGATGGAGCC-3Ј; Serca1-F; 5Ј-GCTCATGGTCCTCAAGATCTCAC-3Ј (10); Serca1-R; 5Ј-GGGTCAGTGCCTCAGCTTTG-3Ј (10); Mbnl1-F; 5Ј-GCTGCCCAATACCAGGTCAAC-3Ј (10); Mbnl1-R; 5Ј-TGGTGGGAGAAATGCTGTATGC-3Ј (10); Ttn-F; 5Ј-GTGTGAGTCGCTCCAGAAACG-3Ј (10); Ttn-R; 5Ј-CCACCACAGGACCATGTTATTTC-3Ј (10); Clcn1-F; 5Ј-GGAATACCTCACACTCAAGGCC-3Ј (11); Clcn1-R; 5Ј-CACGGAACACAAAGGCACTGAATGT-3Ј (11); Tnnt3-F; 5Ј-TCTGACGAGGAAACTGAACAAG-3Ј (11); Tnnt3-R; 5Ј-TGTCAATGAGGGCTTGGAG-3Ј (11); Ptbp1-F; 5Ј-TCTGTCCCTAATGTCCATGG-3Ј; Ptbp1-R; 5Ј-GCCATCTGCACAAGTGCGT-3Ј; Sdc3-F; 5Ј-GCTGTTGCTGCCACCGCT-3Ј; Sdc3-R; 5Ј-GGCGCCTCGGGAGTGCTA-3Ј; Txlnb-F; 5Ј-CTCAGCCCTGCTGCCTGT-3Ј; Txlnb-R; 5Ј-CAGACCCATACGTGCTTATG-3Ј; Mapkap1-F; 5Ј-GTCCGACGCAGCCACAGT-3Ј; Mapkap1-R; 5Ј-CCTTCTCCCTGATTCAGTATA-3Ј.
Western Blotting. DM1 patient 21/200 myoblasts were transfected with PS58 (200 nM) or mock transfected and 72 h later lysed in lysis buffer (1ϫ TBS, 1% Nonidet P-40, 1 mM PMSF and 1ϫ Protease Inhibitory Mixture (Roche, Almere, The Netherlands) on ice. Cleared lysates were separated on an 8% SDS/PAGE gel and transferred to PVDF (Amersham Pharmacia Biotech). Blots were incubated with DMPK-specific antibody B79 (12) and ␤-tubulin monoclonal antibody E7 (Developmental Studies Hybridoma Bank, University of Iowa), followed by ECL detection. Quantification of signals was done using a GS-690 Imaging Densitometer (Bio-Rad) and ImageJ software. Values for mocktreated samples were set at 100.
In Vivo Treatment and Muscle Isolation. One-year-old DM500 mice were anesthetized using isoflurane. The GPS complex was pretreated with PEI-5% glucose injections (0.3 mL insulin syringe with a 30-gauge needle) on days 1 and 2 to improve uptake of PS58. This pretreatment was followed by 2 injections with 2 nmoles PS58 in a PEI-5% glucose solution at the same central position in the GPS muscle on days 3 and 4. In all cases, injection volume was 40 L. Mock-treated mice received exactly the same treatment except that oligo PS58 was left out. Mice were killed on day 15 and individual muscles were isolated, snap frozen in liquid nitrogen, and stored at Ϫ80°C. Diverse treatment protocols were tested in HSA LR mice. In each case, 1 leg of a HSA LR mouse was treated with 1 or 2 nmoles PS58, while the contralateral leg served as mock control. (i) HSA LR mice were injected twice in the GPS complex as described above, without PEI pretreatment. Injections took place at days 1 and 8, and tissues were isolated on day 22. Noninjected TA muscle served as negative control. (ii) TA muscle was injected once as described above, without PEI pretreatment, and muscle tissue was isolated 7 days later. (iii) TA muscle was injected with or without PEI, followed by electroporation (13) and analyzed on day 8 or 15.
Fluorescent in Situ Hybridization. DM500 myoblasts or myotubes grown on gelatin-or Matrigel-coated glass cover slips were fixed in 4% (wt/vol) formaldehyde in PBS for 30 min at room temperature and washed with PBS including 5 mM MgCl 2 . Cells were prehybridized in 40% (vol/vol) formamide/2ϫ SSC for 30 min at room temperature. FAM-labeled and Cy3-labeled 2Ј-OMe PT (CAG)7 probes were used to detect (CUG)n RNA. A fluorescent (CUG)7 probe was used as negative control. Samples were incubated o/n in 125 L probe hybridization buffer (40% (vol/vol) formamide, 2ϫ SSC, 0.2 mg/mL BSA, 10 mg/mL dextran sulfate, 2 mM vanadyl sulfate, 1 mg/mL herring sperm DNA, 30 ng fluorescent oligo) in a humidified chamber at 37°C. Cells were washed 3 times with 40% formamide/2ϫ SSC for 30 min at 37°C, followed by a wash with PBS at room temperature. Cells were mounted in Mowiol (Sigma-Aldrich). FISH on 8 m HSA LR gastrocnemius sections was performed as described, except that 0.2 ng/L Cy3-(CAG)7 probe was present during hybridization and sections were mounted in DAPI-containing Mowiol.
For quantification of nuclear foci, sections were stained, imaged at 1,600ϫ magnification under identical exposure settings, and analyzed using uniform threshold settings. Images were collected on a Zeiss Axioplan fluorescence microscope (Carl Zeiss). Pictures were captured by a Zeiss AxioCam MR camera with Axiovision 3.1 software. In the case of DM500 myoblasts, around 50 nuclei were scored for the presence of foci; size and intensity of foci were not considered during analysis. In HSA LR sections, around 120 nuclei per treatment were classified in 3 groups by 2 or 3 examiners blinded to sample identity. To be able to compare signal intensities, microscope settings were maintained constant.
Immunofluorescence. Frozen 8-m HSA LR gastrocnemius sections were air dried and fixed in 3% (wt/vol) formaldehyde in PBS including 5 mM MgCl 2 , both for 30 min at room temperature. After washing with PBS for 2 minutes, sections were permeabilized in 2% prechilled (Ϫ20°C) acetone in PBS for 5 minutes, washed 5 times with PBS for 2 minutes, and then incubated in anti-Mbnl1 antibody A2764 (10) at 4°C overnight. After washing with PBS, sections were stained with ALEXA 488-coupled secondary antibody at room temperature for 30 min. Sections were washed with PBS and mounted in DAPI-containing Mowiol. Quantification of nuclear Mbnl1 foci was done as described above for (CUG)n foci.
Intratissue Imaging. The distribution of FAM-labeled PS58 was imaged at different time points after injection in the GPS complex of DM500 mice. At different time points, mice were killed, muscles were dissected and analyzed individually. Intravital images were recorded with the Olympus OV110 whole mouse imaging system (Olympus).
Bioinformatics. BLAST analysis of EST and genome databases was done to identify mouse transcripts bearing 1 or more uninterrupted (CUG)n tracts (n Ն 6). Nucleotide query sequences of 6-50 CTG triplets were used. A list of transcripts bearing long (CUG)n segments in the mouse genome is given (Table S2) . HomoloGene was used to identify annotated genes, design primers for PCR, and detect homologs among genes in mouse and human genomes. Expression was predicted on the basis of UniGene information.
Statistical Analysis. DMPK and HSA LR (CUG)250 mRNA signals (Northern blots and RT-PCR) of the experimental group and control group were compared using an unpaired Student's t test. Analysis of (CUG)n-positive nuclei in DM500 myoblasts was done with an unpaired t test. Ribonuclear foci in muscle sections were scored independently by 2 or 3 examiners blinded to sample identities and were compared using a 2 test. Alternative splicing of HSA LR muscle in vivo was analyzed using a paired t test. Spearman's correlation was applied to evaluate whether a correlation exists between DMPK mRNA level and number of CUG triplets in PS58-treated human myoblasts (Fig. 4C) and between splice ratio correction and HSA LR (CUG)250 mRNA levels in PS58-treated muscle (Fig. 5E) . DMPK protein levels in human myoblasts were analyzed using an unpaired t test. All values are presented as the mean Ϯ SEM, unless specified otherwise in the legend. Differences between groups were considered significant when P Ͻ 0.05. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001. Statistical analyses were performed with GraphPad Prism 4 software. (Table S2 ). In all RT-PCR analyses, the (CUG)n tract was present in the amplicon (tract size verified by sequencing). Numerals indicate relative abundance to mock samples, using ␤-actin levels for normalization (mock values set at 100). A representative result of 2 independent experiments is shown. (B) DM500 myotubes were transfected with a concentration series of PS58 (0.01-200 nM) or mock treated. Mapkap1 (CUG)26 RNA levels were measured via semiquantitative RT-PCR using ␤-actin levels for normalization (mock values set at 100). (C) Independently, Northern blotting using total RNA, a Mapkap1 cDNA probe, and a Gapdh probe for normalization essentially confirmed these findings. . Localization and spreading of PS58 oligo after injection in mouse GPS muscle. (A) On 2 consecutive days, fluorescently labeled PS58 was injected in the GPS complex of DM500 mice. One or 14 days after the second injection, presence of fluorescence in muscle tissue was examined using a small-animal imaging system. Oligo was detected in a nonhomogeneous fashion throughout the gastrocnemius, plantaris, and soleus muscle. In general, signal after 14 days was weaker than after 1 day, suggesting breakdown or clearance of the oligo. PS58 could also be detected in the tibialis anterior, but signal was extremely weak. RT-PCR analysis of silencing of individual hDMPK mRNA segments in DM500 mice following PS58 administration. DM500 mice were injected with PS58 or mock injected in the GPS complex. Fifteen days after injection, muscles were isolated and processed for RT-PCR analysis using primer pairs (arrows) covering 5 distinct segments of the hDMPK transcript. Representative results for gastrocnemius and plantaris are shown on the Left. Silencing was quantified per segment (arrowheads), using the ␤-actin signal for normalization, setting mock levels at 100. Per segment, levels from 3 injected mice (including 3 different types of muscle: gastrocnemius, plantaris, and soleus) were averaged (Right column). (See also Fig. 5A ). . Localization of Mbnl1 protein in cell nuclei after PS58 treatment. GPS muscle of HSA LR mice was injected with PS58 or mock injected. Gastrocnemius muscle was isolated and sections were processed for immunofluorescence using an antibody against Mbnl1. Mbnl1 staining was observed in every cell nucleus. Three categories of Mbnl1 localization were scored (Top panels). PS58-treated muscle showed markedly less nuclei with large foci and more nuclei with diffuse Mbnl1 staining, although this distribution did not reach statistical significance (n ϭ 2, P ϭ 0.09, 2 test). Mock PS58 Fig. S7 . Correction of aberrant splicing upon silencing of (CUG)250 mRNA by PS58 in HSA LR mice. TA muscles of 4 mice were electroporated with PS58 in 1 leg and mock treated in the contralateral one. After 8 days, TA muscles were dissected and RNA was isolated. Northern blotting showed that HSA (CUG)250 mRNA levels in PS58-treated muscles were 51 Ϯ 7% compared to mock-treated muscles. Quantification of aberrant splicing was performed via RT-PCR for 5 transcripts known to be aberrantly spliced in DM1 (see Fig. 5D ). Embryonic splice form levels were significantly lowered for 4 out of 5 transcripts (n ϭ 4). All are specific for the hDMPK transcript (see Fig. 2A for locations) . Except PS56, all AONs are modified throughout as indicated: 2ЈOMe ϭ 2Ј-O-methyl sugar modification; PT, phosphorothioate backbone modification; ESE, putative exonic splicing enhancer; NA, not applicable. A bioinformatic approach was used to identify mouse transcripts with uninterrupted (CUG)n segments. A representative, but not necessarily complete, list of long (CUG)n tracts (n Ն 6) in the mouse genome is shown here. Repeat polymorphisms are listed. Four transcripts were tested in RT-PCR (far right column). 
ND
Summary of human transcripts containing long (CUG)n segments (n Ն 10) previously described (14 -20) . Database analysis showed that none of these (CUG)n tracts were actually conserved in mouse (column far right). ND, not determined.
